IRVINE, Calif., Dec. 1, 2015 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC), today announced that its ClearPoint Neuro Navigation System was utilized in the 100th deep brain stimulation (DBS) procedure performed on a dystonia patient at Cook Children's Hospital in Fort Worth, Texas.
"I am extremely pleased with the accuracy and placement of DBS leads utilizing the ClearPoint Neuro Navigation System, which provides my young patients the benefit of sub-millimeter precision in a frameless procedure," said Dr. John Honeycutt, Medical Director, Neurosurgery.
The ClearPoint Neuro Navigation System enables minimally-invasive neurosurgery under continuous MRI guidance, offering surgeons real-time direction and a direct view of the inside of a patient's brain during a procedure. MRI provides more detailed visualization of the brain's tissue compared to other imaging technologies.
About MRI Interventions, Inc.
Building on the imaging power of MRI, MRI Interventions is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain and heart. The ClearPoint system, which has received 510(k) clearance and is CE marked, utilizes a hospital's existing diagnostic or intraoperative MRI suite to enable a range of minimally invasive procedures in the brain. For more information, please visit www.mriinterventions.com.
Forward-Looking Statements
Statements herein concerning MRI Interventions, Inc. (the "Company") plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of these laws. Uncertainties and risks may cause the Company's actual results to differ materially from those expressed in or implied by forward-looking statements. Particular uncertainties and risks include those relating to: customer demand and market acceptance of the Company's products; its ability to successfully expand, and achieve full productivity from, its sales, clinical support and marketing capabilities; its ability to achieve the full benefits from cost reduction efforts that have been implemented or are pending; the sufficiency of its cash resources to maintain planned commercialization efforts; and future actions of the U.S. Food and Drug Administration or any other regulatory body that could impact its commercialization efforts. More detailed information on these and additional factors that could affect the Company's actual results are described in the "Risk Factors" section of the Company's Form 10-K for the year ended December 31, 2014, as well as the Company's Form 10-Q for the quarter ended September 30, 2015, which have been filed with the Securities and Exchange Commission.